Review



custom-made (version 2018.4) analysis apps  (Visiopharm AS)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Visiopharm AS custom-made (version 2018.4) analysis apps
    ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.
    Custom Made (Version 2018.4) Analysis Apps, supplied by Visiopharm AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/custom-made+(version+2018%2E4)+analysis+apps/customized+digital+analysis+apps/pmc10742098-138-9-8
    Average 90 stars, based on 1 article reviews
    custom-made (version 2018.4) analysis apps - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness"

    Article Title: A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness

    Journal: Cancers

    doi: 10.3390/cancers15245773

    ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.
    Figure Legend Snippet: ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.

    Techniques Used: Expressing, Immunohistochemistry, Software, MANN-WHITNEY



    Similar Products

    custom-made (version 2018.4) analysis apps  (Visiopharm AS)
    90
    Visiopharm AS custom-made (version 2018.4) analysis apps
    ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.
    Custom Made (Version 2018.4) Analysis Apps, supplied by Visiopharm AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/custom-made+(version+2018%2E4)+analysis+apps/customized+digital+analysis+apps/pmc10742098-138-9-8
    Average 90 stars, based on 1 article reviews
    custom-made (version 2018.4) analysis apps - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.

    Journal: Cancers

    Article Title: A Novel Metastatic Estrogen Receptor-Expressing Breast Cancer Model with Antiestrogen Responsiveness

    doi: 10.3390/cancers15245773

    Figure Lengend Snippet: ER-expressing primary tumors have a modulated immune landscape compared with TN tumors. ( A ) Representative images of immunohistochemistry of primary TN and ER-expressing 4T1.2 tumors (images at 20×). ( B ) Quantification of tumors for CD68, CD3, CD4, CD8a, CD45r, and neutrophil elastase was performed using the VisioPharm pathology analysis software (Version 2018.4). The percentage of immunoreactive cells out of the total tumor area was determined with a custom-made app. Percentages of positive cells are represented as single values with the mean ± SEM for the ER-expressing and TN 4T1.2 tumors ( n = 12–20). * represents p < 0.05 and ** represents p < 0.005 according to Mann–Whitney test, ns: no significance.

    Article Snippet: To this end, we utilized immunohistochemistry with custom-made VisioPharm (Version 2018.4) analysis apps to determine the percent of total tumor area with immunoreactivity to CD68, CD3, CD4, CD8a, neutrophil elastase, and CD45r.

    Techniques: Expressing, Immunohistochemistry, Software, MANN-WHITNEY